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A B S T R A C T
MicroRNAs (miRNA) are small noncoding RNAs that regulate gene expression by targeting mRNAs in a sequence
specific manner, thereby determining their degradation or inhibiting translation. They are involved in processes
such as proliferation, differentiation and apoptosis by fine-tuning the expression of genes underlying such
events. The expression of specific miRNAs is involved in hematopoietic differentiation and their deregulation
contributes to the development of hematopoietic malignancies such as acute myeloid leukemia (AML). miR-130a
is over-expressed in AML. Here we show that miR-130a is physiologically expressed in myeloblasts and down-
regulated during monocyte differentiation. Gain- and loss-of-function experiments performed on CD34+ human
hematopoietic stem cells confirmed that expression of miR-130a inhibits monocyte differentiation by interfering
with the expression of key transcription factors HOXA10, IRF8, KLF4, MAFB and PU-1. The data obtained in this
study highlight that the correct modulation of miR-130a is necessary for normal differentiation to occur and
confirming that deregulation of this miRNA might underlie the differentiation block occurring in AML.
1. Introduction
miRNAs represent an additional regulatory mechanism in hemato-
poietic stem cells (HSCs) by influencing transcription profiles and
transcript stability [1]. Transcription factors (TF) and miRNAs act in
concert to regulate gene expression during hematopoietic differentia-
tion; TFs regulate the expression of miRNA genes, whereas TFs are key
miRNA targets. Thus, miRNAs represent another axis of regulation in
HSCs, controlling the self-renewal and the fine-tuning of cell fate during
the lineage-specification process. Numerous studies have identified
more than 100 different miRNAs specifically expressed during hema-
topoiesis in mice and humans [2]. In addition, two studies have shown
impaired hematopoiesis after the conditional deletion of Dicer and
Argonaute2, demonstrating the functional impact of miRNAs on normal
hematopoietic process [2–4].
Several miRNAs appear to influence the commitment of HSCs and
their progenitors to monocyte. For instance, miR-146a, miR-155, miR-
342 and miR-338 are upregulated by transcription factor PU.1 [5,6],
which controls myeloid cell development, and ectopic expression of
miR-146a is sufficient to direct HSC differentiation to the mononuclear
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phagocyte lineage in mouse transplantation assays [5]. miR-130a is
aberrantly over-expressed in AML [7], and M1 AML compared to M5
AML and directly targets transcription factors MAFB, IRF8 and KLF4 [8]
that are determinants of monocyte differentiation.
On these grounds, we evaluated how expression of miR-130a is
modulated through myeloid differentiation and in response to a
monocyte differentiation inducer such as vitamin D (VD). Results show
that the selected miRNAs are up-regulated in myeloblasts, compared to
HSCs, while their expression is suppressed in the monocyte lineage and
in HSCs stimulated with VD. To gain further insight on the biological
meaning of these preliminary observations, we performed gain- and
loss-of-function experiments in HSCs. Loss of function experiments were
performed with two different approaches: by transfecting HSCs with
anti-miRNA oligonucleotides or with Peptide Nucleic Acids (PNA) tar-
geting miRNA. PNAs are DNA analogs in which the sugarphosphate
backbone is replaced by N-(2-aminoethyl) glycine units [9]. These
molecules were described for the first time by Nielsen et al. [10] and,
despite a radical structural difference with respect to DNA and RNA,
they are capable of sequence-specific and efficient hybridization with
complementary DNA and RNA, forming Watson-Crick double helices
[11,12]. The efficacy of PNAs in targeting miRNAs was demonstrated
by several works [13–16]. Gain- and loss-of-function assays performed
in HSCs confirmed that expression of miR-130a is tightly related to
monocyte differentiation where, in particular, miRNA’s over-expression
inhibits monocyte differentiation, while miRNA’s silencing favors it.
2. Materials and methods
2.1. Ethics statement
Human CD34+ cells were purified upon donor’s informed written
consent from healthy donor-derived umbilical Cord Blood (CB) sam-
ples, collected after normal deliveries, according to the institutional
guidelines for discarded material (Clearance of Ethical Commitee for
Human experimentation of Modena: Secretary office Saverio
Santachiara, santachiara.saverio@policlinico.mo.it, approval date: 18
January 2005; approval file number # 793/CE).
2.2. Cell population
Cord Blood (CB) CD34+ cells were purified as previously described
[17]. After immunomagnetic separation, CD34+ cells were cultured in
IMDM (Euroclone s.p.a., Milan, Italy) supplemented with 20% FCS (Bio-
Whittaker, Walkersville, MD, USA), in the presence of human hema-
topoietic cytokines: SCF (50 ng/ml), Flt3-ligand (Flt3-l) (50 ng/ml), IL-
11 (50 ng/ml), IL-6 (10 ng/ml), IL-3 (10 ng/ml) and G-CSF (10 ng/ml)
(all from R&D Systems, Minneapolis, MN, USA) [17].
Monoblasts and Myeloblast derived from a 7 days culture of
CD34+were separated using the EasySep Human CD14-Positive
Selection Kit (Stemcell Technologies, Vancouver, Canada) [18]. The
same method is used to collect monocytes from adult peripheral blood
mononuclear cells.
Human granulocytes were collected from cell pellets obtained by
Ficoll separation of PBMCs. Erythrocytes contained in cell pellets were
removed by means of osmotic lysis. Neutrophils (CD16+ fraction) were
then purified using the EasySep Human “Do-It-Yourself” Selection Kit
(Stemcell Technologies) conjugated to mouse Mo anti-human CD16 Ab
(Miltenyi, Auburn, CA) [19].
CD34+ cells, cultured in the same described above conditions, were
stimulate for 7 days with Vitamin D (VD) (Hoffman-Laroche) at
5× 10−8M concentration [17].
2.3. RNA extraction
Total cellular RNA, including small RNAs, was isolated using the
miRVana miRNA Isolation kit (Thermo Fisher Scientific, Austin, TX,
USA) following the manufacturer’s protocol.
For each sample RNA concentration and integrity were assessed by
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies;
Wilmington).
2.4. miRNA precursor molecule and Anti-miRNA inhibitor transfections
miRNA precursor molecule transfections. After separation,
CD34+ cells were cultured in the conditions previously described [19].
After 2 days of culture, the cells were transfected with the Amaxa
Nucleofector Device, using the Human CD34 Cell Nucleofection Kit,
according to the manufacturer’s instructions (Lonza, Basil, Switzer-
land). 5 μg of the following mirVana miRNA mimic, Negative Control #
1, miR-130a-3p, (Thermo Fisher Scientific) were pulsed with the pro-
gram U-008.
Pre-miR Negative Control #1 is a random sequence miRNA pre-
cursor molecule that has been extensively tested in human cell lines and
tissues and validated to not produce identifiable effects on known
miRNA function (http://www.ambion.com).
Anti-miRNA inhibitor transfections. After separation, CD34+ cells
were cultured in the conditions previously described. After 2 days of
culture, they were transfected with the Amaxa Nucleofector Device,
using the Human CD34 Cell Nucleofection Kit, according to the man-
ufacturer’s instructions (Amaxa Biosystem). 5 μg of the following
mirVana miRNA inhibitors, Negative Control #1, miR-130a (Thermo
Fisher Scientific) was pulsed with the program U-008. Anti-miR
Negative Control #1 is a random sequence anti-miRNA inhibitor mo-
lecule that has been extensively tested in human cell lines and tissues
and validated to not produce identifiable effects on known miRNA
function (http://www.ambion.com).
2.5. Quantitative RT-PCR
QRT-PCR was carried out by the ABI PRISM 7900 sequence detec-
tion system (Thermo Fisher Scientific) on total RNAs (100 ng) reverse
transcribed using the High Capacity cDNA Archive Kit (Thermo Fisher
Scientific), according to the manufacturer's instructions. Each cDNA
sample was run in triplicate for targets (MAFB, MMP9, IL-7R, IL-6, TNF-
α, IL-1RA, MRC1, CD163, CD14, CCL2, IL8, IL10Rβ, CEBPβ, GYPa,
MPO) and for GAPDH endogenous control. Thermo Fisher Scientific
supplied primers and probes and the TaqMan Universal Master Mix.
Quantification of QRT-PCR signals was performed using the (2− ΔΔCt)
method, as previously described [20]. The values obtained were re-
presented in terms of relative quantity of mRNA level variations.
miRNAs was reverse transcribed and TaqMan reactions were carried
out using the TaqMan MicroRNA Assays Kit. PCR reactions were per-
formed using TaqMan Universal PCR Master Mix without AmpErase
Uracil N-glycosylase, by means of the ABI PRISM 7900 HT Sequence
Detection Systems (all from Thermo Fisher Scientific).
-CTs and Relative Quantity were calculated, for each detector
using as calibrator the CD34+ sample and the TaqMan Control miRNA
Assay RNU6b as endogenous control.
2.6. CFC assay
After 24 h from the nucleofections, CD34+ cells were plated fol-
lowing the manufacturer’s instructions in MethoCult GF H4434 com-
plete methylcellulose medium for clonogenic assay (StemCell
Technologies) containing a cocktail of recombinant human cytokines:
SCF (50 ng/ml), granulocyte-macrophage colony-stimulating factor
(10 ng/ml), interleukin-3 (10 ng/ml) and EPO (3 U/ml). After 14 days
of culture at 37 °C in a humidified atmosphere with 5% CO2, colonies
were scored as previously described [21].
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2.7. Protein extract preparation and Western blot analysis
Total protein extracts were obtained using a small volume of lysis
buffer (as previously described [22]. 30 μg of extracted protein was
then loaded onto 10% SDS-polyacrylamide gel electrophoresis and
electroblotted to nitrocellulose sheets. Blotted membranes were pre-
blocked for 1 h at room temperature (RT) in blocking solution, com-
posed by 5% nonfat milk (Regilait, Saint-Martin-Belle-Roche, France) in
0.05% TBST or by 3% nonfat milk and 2% BSA (Sigma Aldrich, St.
Louis, MO, USA) in TBST 0.1%, according to antibodies specificity.
The following rabbit anti-human primary antibodies were used at
concentrations recommended by the manufacturer's instruction: MafB
polyclonal Ab (Sigma-Aldrich), Klf4 (Abcam, Cambridge, UK), Irf8 and
Hox10 (Santa Cruz Biotechnology, Dallas, Texas, USA).
As a secondary antibody, conjugated to horse-radish peroxidase, we
used a goat anti-rabbit IgG (Cell Signaling Technology) at 1:3000 di-
lutions. To normalize analyzed protein samples, a rabbit anti-human
vinculin polyclonal Ab (Millipore Corporation, Billerica, MA, USA)
were used. Detection of Western blot signals was carried out using the
Westar EtaC enhanced chemiluminescent substrate (Cyanagen S.r.l.,
Bologna, Italy).
2.8. Morphological and immunophenotypic analysis
Differentiation of CD34+ cells was assessed by morphological ana-
lysis with May-Grunwald-Giemsa staining and by flow-cytometric
analysis of differentiation markers expression 8 day after the nucleo-
fection.
The following monoclonal antibodies (MoAbs) were used for flow
cytometric analysis: fluorescein isothiocyanate (FITC)-conjugated
mouse anti-CD14 MoAb, phycoerythrin (PE)-conjugated mouse anti-
human CD163 MoAb (all from Miltenyi Biotec, Bergisch Gladbach,
Germany). Analysis was performed in terms of positivity percentage
with the Coulter Epics XL-MCL (Coulter Electronics, Hialeah, FL) flow
cytometer as previously described [23]. At least 10,000 events for
sample were acquired.
2.9. Peptide nucleic acids synthesis
If not otherwise mentioned, chemicals and solvents were purchased
from Sigma Aldrich, Alfa Aesar, or Scharlab, and used without any
further purification. DMF was dried over 4 Å molecular sieves and
purged with nitrogen to avoid the presence of dimethylamine.
The synthesis and characterization of PNAs was similar to those
previously reported [24]. The synthesis was performed using standard
Fmoc-based automatic peptide synthesizer (Syro I, MultiSynTech
GmbH, Witten, Germany), using a ChemMatrix-RinkAmide resin loaded
with Fmoc-Gly-OH (0.2 mmol/g) as first monomer and using commer-
cially available Fmoc/Bhoc PNA monomers (Link Technologies, Bells-
hill, UK) and Fmoc-Arg (Pbf)-OH, with HBTU/DIPEA coupling. Clea-
vage from the solid support was performed with 10% m-cresol in
trifluoroacetic acid (TFA), followed by precipitation and washings with
diethyl ether. Purification was performed by HPLC using a Jupiter
RPC18 column (250×4.6mm, 1.7 μm, Phenomenex, Torrance, Ca,
USA). Gradient: 100% A for 5min, then from 0 to 50% B in 30min at
4mL/min flow (A: 0.1% TFA in water; B: 0.1% TFA in acetonitrile).
Column temperature: 40 °C. After purification the PNAs were char-
acterized by UPLC-MS or by HPLC-HRMS. For UPLC-MS the following
conditions were used: Waters Acquity Ultra Performance LC with Wa-
ters SQ detector, and equipped with Waters UPLC BEH 300 column
(50× 2.1mm, 1.7 μm, C18). A flow rate of 0.25ml/min was used with
the following solvent systems: (A): 0.2% FA in water and (B): 0.2% FA
in acetonitrile (FA= formic acid). The column was flushed for 0.9 min
with solvent A, then a gradient from 0 to 50% B in 5.7min was used.
For HPLC-HRMS the following HPLC-MS instrumental set-up was
used: DIONEX Ultimate3000 system (Thermo Scientific Waltham, MA,
USA) coupled with a LTQ Orbitrap XL spectrometer (Thermo
Scientific); Software: Xcalibur 2.0.7 SP1 (Thermo Fisher Scientific
Waltham, MA, USA) Column: AERIS Peptides 3.6 u XB-C18
150 × 2.1 mm (Phenomenex). Chromatographic condition: eluent A:
water +0.2% formic acid; eluent B: acetonitrile +0.2% Formic acid.
Column temperature: 35 °C. Program: initial isocratic at 10% B (5 min),
then linear gradient to 95% B (in 25 min). Flow rate: 0.2 mL/min. The
concentrations of the PNAs were calculated using UV-absorbance at
260 nm assuming an additive contribution of all bases
(ε=198,000M−1cm−1 for all PNAs). R8-PNA-a130a: sequence H-R8-
CCTTTTAACATTGCACTG-Gly-NH2; yield 8.2%; HPLC-HRMS
Rt=12.47min, calculated MW: 6127.29 g/mol; m/z found (calcu-
lated): 1532.70 (1532.82) [MH4]4+, 1226.36 (1226.46) [MH5]5+,
1022.13 (1022.22) [MH6]6+, 876.26 (876.33) [MH7]7+, 766.85
(766.91) [MH8]8+, 681.76 (681.81) [MH9]9+, 613.68 (613.73)
[MH10]10+. R8-PNA-MIS-130a: sequence H-R8-CCATTTTACAATGCT
CTG-Gly-NH2; yield 8.18%; HPLC-MS Rt=12.53min, calculated MW:
6127.29 g/mol; m/z found (calculated): 1532.70 (1532.82) [MH4]4+,
1226.36 (1226.46) [MH5]5+, 1022.14 (1022.22) [MH6]6+, 876.26
(876.33) [MH7]7+, 766.85 (766.91) [MH8]8+, 681.76 (681.81)
[MH9]9+,613.68 (613.73) [MH10]10+. R8-PNA-SCR-130a: sequence H-
R8-ATCTCGTATCTATCCTGA-Gly-NH2; yield 12.52% (after purifica-
tion); HPLC-HRMS Rt=11.95min, calculated MW: 6127.29 g/mol; m/
z found (calculated): 1532.70 (1532.82) [MH4]4+, 1226.36 (1226.46)
[MH5]5+, 1022.13 (1022.22) [MH6]6+, 876.26 (876.33) [MH7]7+,
766.85 (766.91) [MH8]8+, 681.76 (681.81) [MH9]9+,613.68 (613.73)
[MH10]10+, 557.99 (558.03) [MH11]11+.
2.10. PNA transfection
PNA and controls were directly added to the cellular medium at a
final concentration of 2 μM in HSCs. Western blots on transcription
factors were performed 48 h after treatment, clonogenic assays were
counted two weeks following PNA treatment. Cell morphology was
assessed a week after treatment.
3. Results
Expression of miR-130a in normal haematopoiesis. Fig. 1A re-
presents a Real Time quantitative PCR (QRTPCR) showing the expres-
sion level of miR-130A in myeloblasts, monoblasts, granulocytes and
monocytes compared to HSCs. Results show that miR-130a is up-
regulated in myeloblasts and down-regulated in the other three ana-
lyzed cell contexts compared to HSCs. A direct comparison, obtained by
QRTPCR, between the expression of miR-130a in monoblasts and
myeloblasts is shown in Fig. 1B, confirming miR-130a down-regulation
in monoblasts. Fig. 1C depicts another QRTPCR showing expression
levels of miR-130a in HSCs before and after treatment with the
monocyte differentiation inducer vitamin D (VD). This experiment
shows that miR-130a is down-regulated upon VD induced differentia-
tion.
Ectopic expression of miR-130a in human
CD34+ haematopoietic stem cells. In this set of experiments, HSCs
were nucleofected with pre-miR-130a. Effects of ectopic expression
were analyzed by different approaches. Fig. 2A summarizes a methyl-
cellulose assay showing that, upon miR-130a ectopic expression, a
statistically significant increase in “colony-forming-units granulocyte/
monocyte” (CFU-GM) coupled to a decrease of “colony forming units
monocyte” (CFU-M) occurs. Fig. 2B represents a QRTPCR performed on
a pattern of monocyte-related genes. Following ectopic expression of
miR-130a, there is a general and statistically significant down-regula-
tion of such genes, among whom CD14, CD163, IL1a, IL7R and MMP9
are particularly relevant. Myeloperoxidase (MPO), whose expression
does not change, is a granulocyte-related gene that was added as a
specificity control.
Fig. 2C summarizes the flow cytometry analysis showing the
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percentage of cells positive to CD14 and CD163 in untreated HSCs and
in cells ectopically expressing miR-130a. Following miRNA expression,
a reduction of both CD14 and CD163 positivity is observed. Fig. 2D
shows a Western blot analysis of several key transfection factors related
to monocyte differentiation. Upon miR-130a over-expression in HSCs,
they appear to be generally down-regulated also at the protein level.
Effect of miR-130a silencing in human CD34+ haematopoietic
stem cells. HSCs were transfected with Anti miR-130a in order to block
its expression and observe the effect on haematopoietic differentiation.
Fig. 3A shows that, upon miR-130a silencing, in a methylcellulose assay
one can observe a reduction of CFU-GM and an increase of CFU-M,
opposite to what was observed in the “gain of function” set of experi-
ments. Fig. 3B represents a QRTPCR showing that miR-130a silencing
in HSCs determines the upregulation of monocyte-related genes (IL7R,
MMP9 and MRC1), which is coupled to increased positivity to mono-
cyte markers CD14 and CD163, as demonstrated by flow cytometry
analysis (Fig. 3C). Fig. 3D depicts a Western blot demonstrating that the
increased expression of monocyte markers is also coupled to up-reg-
ulation of monocyte transcription factors IRF8, KLF4 and MAFB, that
have already been described as miR-130a targets [8].
Effect of specific PNA targeting miR-130a on haematopoietic
differentiation. Since miR-130a expression is de-regulated in AML, we
tested the efficacy of PNA targeting this microRNA, to evaluate PNAs’
efficacy in inhibiting miR-130a expression and their effect on
haematopoietic differentiation. Fig. 4A summarizes the results of a
methylcellulose assay performed on HSCs untreated or treated respec-
tively with scramble, degenerate and PNA-a130a. Results show that the
decrease of CFU-GM and the increase of CFU-M comparable to that
observed by anti-miRNA treatment (Fig. 3A) is observed only by anti-
miR-130a PNA treatment. Western blot analysis shown in Fig. 4B sug-
gests that up-regulation of monocyte transcription factors IRF8, KLF4
and MAFB occurs only in HSCs treated with the specific PNA targeting
Fig. 1. Expression of miR-130a in normal haematopoiesis. (A) QRTPCR
showing that among different myeloid contexts, miR-130a is especially ex-
pressed in myeloblasts while it is down-regulated in monoblasts, granulocytes
and monocytes. (B) QRTPCR confirming miR-130a down-regulation in mono-
blasts. (C) QRTPCR showing that VD treatment inhibits miR-130a expression in
HSCs. In all experiments mean variations of mRNA expression levels, deriving
from at least three independent experiments, are reported in the y axis as re-
lative fold-change (relative quantity). Results are represented as
mean ± S.E.M. values and asterisks indicate statistically significant results
(P < 0.05).
Fig. 2. Effect of ectopic expression of miR-130a in human
CD34+ haematopoietic stem cells. (A) Methylcellulose assay showing that miR-
130a ectopic expression determines an increase of CFU-GM coupled to a de-
crease of CFU-M. The number of colonies on the Y axis derives from at least
three independent experiments. Results are represented as mean ± S.E.M.
values and asterisks indicate statistically significant results (P < 0.05). (B)
QRTPCR showing the expression of a pattern of monocyte-related genes in HSCs
following miR-130a ectopic expression. Mean variations of mRNA expression
levels, deriving from at least three independent experiments, are reported in the
y axis as relative fold-change (relative quantity). Results are represented as
mean ± S.E.M. values and asterisks indicate statistically significant results
(P < 0.05). (C) Flow cytometry analysis showing the percentage of cells po-
sitive to CD14 and CD163 respectively, following ectopic expression of miR-
130a in CD34+ cells. The percentage of positivity shown on the y axis derives
from at least three independent experiments. Results are represented as
mean ± S.E.M. values and asterisks indicate statistically significant results
(P < 0.05). (D) Western blot analysis performed on monocyte differentiation
related transcription factors following ectopic expression of miR-130a in
CD34+ stem cells. This analysis was performed on total protein extracts and
normalized with Vinculin. Analyzed proteins are indicated on the left.
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miR-130a. Moreover, cells where miR-130a was silenced by PNA
treatment, show higher positivity to CD163 differentiation marker than
the control, as shown by flow cytometry analysis (Fig. 4C). Fig. 4D
depicts a May-Grunwald staining of HSCs untreated or treated with
PNA-a130a. The picture shows a randomly selected field suggesting
that the cell population not expressing the miRNA is richer in mono/
macrophages than the control.
Effect of specific PNA targeting miR-130a on different leukemic
cell lines. Since we hypothesized that PNAs might be a therapeutic tool
targeting micro-RNAs, we analyzed its effect, from a molecular point of
view, on selected leukemic cell lines. In particular we performed a
Western blot targeting MAFB, IRF8 and KLF4 in U937 cells that are
responsive to monocyte differentiation induction by phorbol esters
(PMA) and VD. Fig. 5A shows that following PNA treatment the three
genes are all upregulated compared to the control. Then we analyzed
MAFB induction in several other cell lines responsive or unresponsive to
monocyte differentiation inducers. Results are shown in Fig. 5B and
suggest that MAFB is induced by PNA treatment only in cell lines that
respond to monocyte differentiation inducers (Kasumi, U937 and HL-
60) and not in un-responsive cell lines (K562 and NB4) suggesting that
targeting miR-130a might be useful in specific forms of AML.
4. Discussion
TFs and miRNAs act in concert to regulate gene expression during
hematopoietic differentiation: TFs regulate the expression of miRNA
Fig. 3. Effect of miR-130a silencing in human CD34+ stem cells. (A)
Methylcellulose assay showing that miR-130a silencing determines a decrease
of CFU-GM coupled to an increase of CFU-M. The number of colonies on the Y
axis derives from at least three independent experiments. Results are re-
presented as mean ± S.E.M. values and asterisks indicate statistically sig-
nificant results (P < 0.05). (B) QRTPCR showing that miR-130a silencing in
CD34+ cells determines the up-regulation of monocyte-related genes IL7R,
MMP9 and MRC1. Mean variations of mRNA expression levels, deriving from at
least three independent experiments, are reported in the y axis as relative fold-
change (relative quantity). Results are represented as mean ± S.E.M. values
and asterisks indicate statistically significant results (P < 0.05). (C) Flow cy-
tometry analysis showing the percentage of cells positive to CD14 and CD163
respectively, following silencing of miR-130a in CD34+ cells. The percentage of
positivity shown on the y axis derives from at least three independent experi-
ments. Results are represented as mean ± S.E.M. values and asterisks indicate
statistically significant results (P < 0.05). (D) Western blot analysis performed
on monocyte markers following silencing of miR-130a in CD34+ stem cells.
This analysis was performed on total protein extracts and normalized with
Vinculin. Analyzed proteins are indicated on the left.
Fig. 4. Effect of specific PNA targeting miR-130a on haematopoietic differ-
entiation. (A) Methylcellulose assay performed on HSCs untreated or treated
with scramble (PNA-SCR-a130a), degenerate (PNA-MIS-a130a) or miR-130a
targeting PNA (PNA-a130a). The number of colonies on the Y axis derives from
at least three independent experiments. Results are represented as
mean ± S.E.M. values and asterisks indicate statistically significant results
(P < 0.05). (B) Western blot analysis showing the expression of IRF8, MAFB
and KLF4 in HSCs treated with scramble, degenerate or specific PNA (PNA-
a130a). This analysis was performed on total protein extracts and normalized
with Vinculin. (C) Flow cytometry analysis showing the percentage of HSCs
positive to CD163, following treatment with degenerate (PNA-MIS-a130a) or
specific PNA (PNA-a130a). (D) May-Grunwald staining of HSCs untreated or
treated with PNA-a130a.
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genes, and they are directly targeted by miRNAs. miRNAs represent an
important axis of regulation in HSCs: they play a critical role in the
control of stem/progenitor, lymphoid, myeloid, erythroid and mega-
karyocytic biology, and in the immune function of these cell lineages
[25]. Moreover, individual miRNAs and miRNA signatures have been
associated with specific hematological malignancies.
Acute myeloid leukemia is characterized by an accumulation of
granulocytic or monocyte precursors in bone marrow and peripheral
blood. miRNA patterns have been correlated with cytogenetic and
molecular subtypes of AML [26]. Comparing the microRNA expression
profiles of M1 and M5 AML, Lutherborrow et al. [8] found higher levels
of miR-181a/b/d, miR-130a, miR-135b, miR-146a/b and miR-663 in
M1 AML samples. Interestingly, the targets of these miRNAs are key
transcription factors involved in monocyte/macrophage differentiation:
KLF4, MAFB, HOXA10 and IRF8.
In order to evaluate the role or miR-130a during monocyte differ-
entiation, we analyzed the expression of miR-130a during myelopoiesis.
The data obtained showed that miR-130a is significantly higher in
myeloblasts. These results correlate well with the fact that miR-130a-3p
targets HOXA10, IRF8, KLF4 and MAFB [8] that are considered master
regulators of monocyte differentiation [27–32].
To confirm the decrease of the two studied miRNAs in mono-
cytopoiesis, we stimulated HSCs with Vitamin D, that is a strong in-
ductor of monocyte-macrophage stimulation. As expected, a decrease of
miR-130a expression was observed, further suggesting that down-reg-
ulation of miR-130a is necessary to trigger monocyte differentiation.
These data also suggest that miR-130a misregulation might contribute
to aberrant monocytopoiesis.
Gain- and loss-of-function experiments confirmed that by acting on
miR-130a expression it is possible to impinge on monocyte differ-
entiation. Since deregulation of this miRNA has been described in AML,
we hypothesized that they could represent a therapeutic target for
certain disease subgroups. For this reason, we decided to verify the
efficacy of peptide nucleic acids (PNA) to silence the expression of miR-
130a in HSCs. PNAs have very important properties: thermal stability,
strong binding to RNA, capacity to form stable triple-helical complex,
greater specificity of interaction, resistance to nucleases and proteases
and some recent modifications, including the incorporation of posi-
tively charged lysine residues, have shown improvements in solubility.
The results obtained show a strong uptake of PNA-a130a in absence of
transfection reagent in hematopoietic stem cells that are hard to
transfect. The analysis performed at day 14 of culture confirmed that
PNA is very stable and that a single treatment is sufficient to have an
antimiR effect.
The evaluation of monocyte differentiation in HSCs treated with
anti-miR-130a PNA, documents a higher increase of monocytopoiesis
when compared with the samples treated with anti-miR molecules,
demonstrating that the biological effect of PNAs in modulating miRNA
expression is strong and very stable. This last set of data highlights that
the modulation of miR-130a expression is necessary to a correct mye-
loid differentiation, and throws the basis for a possible future use of
PNA-a130a as therapeutic agent to restore a correct gene expression in
hematological malignancies like AML. This latter hypothesis is re-
inforced by the observation that anti-miR-130a treatment is capable of
inducing the expression of the monocyte master gene MAFB in cell lines
responsive to monocyte differentiation inducers, suggesting its efficacy
in specific subsets of the disease.
Author disclosure statement
All the authors certify that they have NO competing financial in-
terest and conflict of interest in the subject matter or materials dis-
cussed in this manuscript.
Acknowledgement
The work was funded by grant FAR2015 provided by the University
of Modena and Reggio Emilia.
References
[1] L.M. Starnes, A. Sorrentino, Regulatory circuitries coordinated by transcription
factors and microRNAs at the cornerstone of hematopoietic stem cell self-renewal
and differentiation, Curr. Stem Cell Res. Ther. 6 (2) (2011) 142–161.
[2] R.M. O'Connell, et al., MicroRNAs enriched in hematopoietic stem cells differen-
tially regulate long-term hematopoietic output, Proc. Natl. Acad. Sci. U. S. A. 107
(32) (2010) 14235–14240.
[3] S.A. Muljo, et al., Aberrant T cell differentiation in the absence of Dicer, J. Exp.
Med. 202 (2) (2005) 261–269.
[4] D. O'Carroll, et al., A Slicer-independent role for Argonaute 2 in hematopoiesis and
the microRNA pathway, Genes Dev. 21 (16) (2007) 1999–2004.
[5] S. Ghani, et al., Macrophage development from HSCs requires PU.1-coordinated
microRNA expression, Blood 118 (8) (2011) 2275–2284.
[6] J. Jurkin, et al., miR-146a is differentially expressed by myeloid dendritic cell
subsets and desensitizes cells to TLR2-dependent activation, J. Immunol. 184 (9)
(2010) 4955–4965.
[7] Chao Ding, et al., MiR-130a is aberrantly overexpressed in adult acute myeloid
leukemia with t(8;21) and its suppression induces AML cell death, Ups. J. Med. Sci.
123 (1) (2018) 19–27.
[8] M. Lutherborrow, et al., Expression profiling of cytogenetically normal acute
myeloid leukemia identifies microRNAs that target genes involved in monocytic
differentiation, Am. J. Hematol. 86 (1) (2011) 2–11.
[9] R. Gambari, Peptide nucleic acids: A review on recent patents and technology
transfer, Expert Opin. Ther. Pat. 24 (3) (2014) 267–294.
[10] P.E. Nielsen, et al., Sequence-selective recognition of DNA by strand displacement
with a thymine-substituted polyamide, Science 254 (5037) (1991) 1497–1500.
[11] M. Egholm, et al., PNA hybridizes to complementary oligonucleotides obeying the
Watson-Crick hydrogen-bonding rules, Nature 365 (6446) (1993) 566–568.
[12] V.L. Marin, S. Roy, B.A. Armitage, Recent advances in the development of peptide
Fig. 5. Western blot analysis showing the induction of
monocyte specific transcription factors in cell lines
treated with miR-130a targeting PNA. Panel A shows the
induction of MAFB, KLF4 and IRF8 in the U937 cell line.
Panel B shows the induction of MAFB in Kasumi, U937,
HL-60, K562 and NB4 cell lines. These analysis were
performed on total protein extracts and normalized with
Vinculin.
F. Mammoli, et al. Experimental Cell Research 382 (2019) 111445
6
nucleic acid as a gene-targeted drug, Expert Opin. Biol. Ther. 4 (3) (2004) 337–348.
[13] M.M. Fabani, M.J. Gait, miR-122 targeting with LNA/2'-O-methyl oligonucleotide
mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates, RNA 14 (2)
(2008) 336–346.
[14] S.Y. Oh, Y. Ju, H. Park, A highly effective and long-lasting inhibition of miRNAs
with PNA-based antisense oligonucleotides, Mol. Cells 28 (4) (2009) 341–345.
[15] M.M. Fabani, et al., Efficient inhibition of miR-155 function in vivo by peptide
nucleic acids, Nucleic Acids Res. 38 (13) (2010) 4466–4475.
[16] E. Fabbri, et al., Modulation of the biological activity of microRNA-210 with pep-
tide nucleic acids (PNAs), ChemMedChem 6 (12) (2011) 2192–2202.
[17] c. Gemelli, et al., The Orosomucoid 1 protein is involved in the vitamin D-mediated
macrophage de-activation process, Exp. Cell Res. 319 (20) (2013 Dec) 3201–3213.
[18] M. Montanari, et al., Correlation between differentiation plasticity and mRNA ex-
pression profiling of CD34+-derived CD14− and CD14+ human normal myeloid
precursors, Cell Death Differ. 12 (2005) 1588–1600.
[19] E. Tenedini, et al., Integrated analysis of microRNA and mRNA expression profiles
in physiological myelopoiesis: Role of Hsa-mir-299-5p in CD34+ progenitor cells
commitment, Cell Death Dis. 1 (2) (2010) e28–.
[20] L. Montorsi, et al., Expression of μ-protocadherin is negatively regulated by the
activation of the β-catenin signaling pathway in normal and cancer colorectal en-
terocytes, Cell Death Dis. 7 (2016 Jun 16) e2263.
[21] T. Vignudelli, et al., ZFP36L1 negatively regulates erythroid differentiation of
CD34+ hematopoietic stem cells by interfering with the Stat5b pathway, Mol. Biol.
Cell 21 (19) (2010 Oct) 3340–3351.
[22] C. Gemelli, et al., MafB is a downstream target of the IL-10/STAT3 signaling
pathway, involved in the regulation of macrophage de-activation, Biochim.
Biophys. Acta 1843 (5) (2014 May) 955–964.
[23] C. Gemelli, et al., The vitamin D3/Hox-A10 pathway supports MafB function during
the monocyte differentiation of human CD34+ hemopoietic progenitors, J.
Immunol. 181 (8) (2008 Oct 15) 5660–5672.
[24] G. Montagner, et al., Peptide nucleic acids targeting Β-globin mRNAs selectively
inhibit hemoglobin production in murine erythroleukemia cells, Int. J. Mol. Med.
35 (1) (2015) 51–58 PMC.
[25] C.Z. Chen, et al., MicroRNAs modulate hematopoietic lineage differentiation,
Science 303 (5654) (2004) 83–86.
[26] M. Jongen-Lavrencic, et al., MicroRNA expression profiling in relation to the ge-
netic heterogeneity of acute myeloid leukemia, Blood 111 (10) (2008) 5078–5085.
[27] M.W. Feinberg, et al., The Kruppel-like factor KLF4 is a critical regulator of
monocyte differentiation, EMBO J. 26 (2007) 4138–4148.
[28] C. Gemelli, et al., Virally mediated MafB transduction induces the monocyte com-
mitment of human CD34+ hematopoietic stem/progenitor cells, Cell Death Differ.
13 (2006) 1686–1696.
[29] T. Zanocco-Marani, et al., Tfe3 expression is closely associated to macrophage
terminal differentiation of human hematopoietic myeloid precursors, Exp. Cell Res.
312 (2006) 4079–4089.
[30] T. Zanocco-Marani, et al., Tfe-3 transcription factor regulates the expression of
MafB during macrophage differentiation, Exp. Cell Res. 315 (2009) 1798–1808.
[31] P. Italiani, et al., Transcriptomic profiling of the development of the inflammatory
response in human monocytes in vitro, PLoS One 9 (2014) e87680.
[32] T. Tamura, D. Kurotaki, S. Koizumi, Regulation of myelopoiesis by the transcription
factor IRF8, Int. J. Hematol. 101 (2015) 342–351, https://doi.org/10.1007/
s12185-015-1761-9.
F. Mammoli, et al. Experimental Cell Research 382 (2019) 111445
7
